afuresertib

Ligand id: 7890

Name: afuresertib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 101.18
Molecular weight 426.05
XLogP 3.15
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Afuresertib is being assessed in Phase II clinical trials, either as a monotherapy (NCT01531894) or in combination with other anti-neoplastic therapeutics (NCT01532700 with ofatumumab for relapsed and refractory chronic lymphocytic leukemia, and NCT01653912 with carboplatin and paclitaxel for platinum-resistant ovarian cancer).
Mechanism Of Action and Pharmacodynamic Effects
The PI3K/AKT pathway is constitutively active in hematologic malignancies, therefore inhibition can help reduce the proliferative and antiapoptotic signals arising from this aberrant signalling.